The navigation below allows you to jump to any table or figure within the SEER Cancer Statistics Review.

  1. First select the CSR Section, then a Table/Figure from that section.
  2. Use the Submit button to view the table or figure. You will have options to download a printer-friendly version (PDF) or the data table (CSV) as well.

To learn more about the Cancer Statistics Review and the statistics presented in this report, refer to the About the CSR (PDF, 528 KB) and Technical Notes (PDF, 794 KB) pages.

Download and Print: Download Printer-friendly PDF Download data

Table 8.21

Cancer of the Esophagus (Invasive)

United States Cancer Prevalence Estimates

Estimated United States Cancer Prevalence Counts a on January 1, 2017
By Race/Ethnicity, Sex and Years Since Diagnosis

Race/Ethnicity Sex Years Since Diagnosis Completee
0 to 5 >5 to 10 >10 to 15 >15 to 20 >20 to 25 <=25b >25d
All Races Both Sexes 27,474 9,941 5,094 2,733 970 46,212 1,478 47,690
Males 21,530 7,591 3,804 2,132 744 35,800 978 36,777
Females 5,944 2,350 1,290 601 227 10,412 500 10,912
White Both Sexes 24,528 9,166 4,657 2,491 805 41,646 1,177 42,823
Males 19,465 7,136 3,561 1,992 639 32,792 812 33,605
Females 5,063 2,031 1,096 499 166 8,854 364 9,218
Black Both Sexes 1,946 502 291 168 117 3,025 185 3,209
Males 1,334 260 147 98 71 1,909 78 1,988
Females 613 242 144 71 46 1,116 106 1,222
Asian/
Pacific
Islander		 Both Sexes 678 176 88 55 23 1,020 + +
Males 508 107 52 37 18 721 + +
Females 170 69 36 19 5 299 + +
Hispanic Both Sexes 1,481 454 166 103 58 2,262 + +
Males 1,195 359 132 97 48 1,831 + +
Females 286 95 34 6 11 431 + +

Estimated prevalence percent a on January 1, 2017, of the SEER population diagnosed in the previous 25 years
By Age at Prevalence, Race/Ethnicity and Sex

Race/Ethnicity Sex Age Specific (Crude) Age-Adjustedc
All Ages 0-9 10-19 20-29 30-39 40-49 50-59 60-69 70-79 80+ All Ages
All Races Both Sexes 0.0143 - - 0.0001 0.0005 0.0026 0.0128 0.0407 0.0739 0.0734 0.0117
Males 0.0224 - - 0.0002 0.0007 0.0039 0.0211 0.0679 0.1276 0.1357 0.0201
Females 0.0063 - - 0.0001 0.0003 0.0012 0.0048 0.0161 0.0290 0.0346 0.0048
White Both Sexes 0.0165 - - 0.0001 0.0005 0.0028 0.0135 0.0439 0.0804 0.0771 0.0126
Males 0.0261 - - 0.0002 0.0007 0.0045 0.0223 0.0737 0.1386 0.1439 0.0217
Females 0.0069 - - 0.0000 0.0003 0.0011 0.0049 0.0163 0.0307 0.0347 0.0049
Black Both Sexes 0.0066 - - 0.0001 0.0007 0.0020 0.0110 0.0279 0.0342 0.0441 0.0072
Males 0.0087 - - - 0.0009 0.0016 0.0183 0.0389 0.0540 0.0684 0.0108
Females 0.0047 - - 0.0002 0.0005 0.0023 0.0047 0.0191 0.0204 0.0319 0.0046
Asian/
Pacific
Islander		 Both Sexes 0.0049 - - 0.0002 - 0.0013 0.0059 0.0159 0.0320 0.0420 0.0053
Males 0.0072 - - - - 0.0016 0.0091 0.0288 0.0481 0.0690 0.0085
Females 0.0028 - - - - 0.0010 0.0031 0.0056 0.0192 0.0243 0.0029
Hispanic Both Sexes 0.0039 - - 0.0001 0.0001 0.0021 0.0063 0.0198 0.0391 0.0413 0.0063
Males 0.0062 - - 0.0002 0.0001 0.0034 0.0109 0.0340 0.0741 0.0789 0.0114
Females 0.0015 - - - 0.0002 0.0007 0.0018 0.0072 0.0121 0.0179 0.0022

Footnotes:

a US 2017 cancer prevalence counts are based on 2017 cancer prevalence proportions from the SEER 13 Areas (excluding the Alaska Native Registry) and 1/1/2017 US population estimates based on the average of 2016 and 2017 population estimates from the US Bureau of the Census. Prevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 25 years.

b Maximum limited-duration prevalence is 25 years for 1992-2017 data.

c Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groups.

d Cases diagnosed more than 25 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000).

e Complete prevalence is obtained by summing <=25 and >25.

- Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

+ Not available.

Page Navigation: << Previous Next >>

The information on this page is archived and provided for reference purposes only. Persons with disabilities having difficulty accessing information on this page may e-mail for assistance.